Company news

Biogen Inc. news in 2024

Biogen Inc.'s news releases, calls and decks from 2024, newest first.

View company

"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico

December 3, 2024

"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea

November 26, 2024

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

November 13, 2024

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

October 28, 2024

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

October 28, 2024

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

October 27, 2024

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

October 25, 2024

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

October 23, 2024

Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024

October 21, 2024

Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients

October 8, 2024

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

October 7, 2024

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

September 23, 2024

Biogen Board Appoints Two New Independent Directors

September 11, 2024

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

September 3, 2024

Leqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

August 21, 2024

New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Alzheimer's Association International Conference (AAIC...

July 29, 2024

New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC...

July 29, 2024

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

July 29, 2024

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

July 25, 2024

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor

July 23, 2024

Biogen Completes Acquisition of Human Immunology Biosciences

July 1, 2024

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China

June 26, 2024

TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union

June 23, 2024

Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel

June 2, 2024

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

May 29, 2024

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

May 21, 2024

Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

May 15, 2024

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

May 15, 2024

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

May 13, 2024

Biogen Reports Progress on Corporate Responsibility Priorities

May 1, 2024

Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®

April 24, 2024

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

March 5, 2024

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

March 3, 2024

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

February 22, 2024

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

February 11, 2024

Biogen to Realign Resources for Alzheimer's Disease Franchise

January 30, 2024

Calls in 2024

Decks in 2024